↓ Skip to main content

A validated antibody panel for the characterization of tau post-translational modifications

Overview of attention for article published in Molecular Neurodegeneration, November 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

twitter
16 X users
patent
5 patents
facebook
1 Facebook page

Citations

dimensions_citation
64 Dimensions

Readers on

mendeley
148 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A validated antibody panel for the characterization of tau post-translational modifications
Published in
Molecular Neurodegeneration, November 2017
DOI 10.1186/s13024-017-0229-1
Pubmed ID
Authors

Ebru Ercan, Sameh Eid, Christian Weber, Alexandra Kowalski, Maria Bichmann, Annika Behrendt, Frank Matthes, Sybille Krauss, Peter Reinhardt, Simone Fulle, Dagmar E. Ehrnhoefer

Abstract

Tau is a microtubule-binding protein, which is subject to various post-translational modifications (PTMs) including phosphorylation, methylation, acetylation, glycosylation, nitration, sumoylation and truncation. Aberrant PTMs such as hyperphosphorylation result in tau aggregation and the formation of neurofibrillary tangles, which are a hallmark of Alzheimer's disease (AD). In order to study the importance of PTMs on tau function, antibodies raised against specific modification sites are widely used. However, quality control of these antibodies is lacking and their specificity for particular modifications is often unclear. In this study, we first designed an online tool called 'TauPTM', which enables the visualization of PTMs and their interactions on human tau. Using TauPTM, we next searched for commercially available antibodies against tau PTMs and characterized their specificity by peptide array, immunoblotting, electrochemiluminescence ELISA and immunofluorescence technologies. We demonstrate that commercially available antibodies can show a significant lack of specificity, and PTM-specific antibodies in particular often recognize non-modified versions of the protein. In addition, detection may be hindered by other PTMs in close vicinity, complicating the interpretation of results. Finally, we compiled a panel of specific antibodies and show that they are useful to detect PTM-modified endogenous tau in hiPSC-derived neurons and mouse brains. This study has created a platform to reliably and robustly detect changes in localization and abundance of post-translationally modified tau in health and disease. A web-based version of TauPTM is fully available at http://www.tauptm.org .

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 148 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 36 24%
Researcher 23 16%
Student > Bachelor 16 11%
Student > Doctoral Student 16 11%
Student > Master 10 7%
Other 12 8%
Unknown 35 24%
Readers by discipline Count As %
Neuroscience 33 22%
Biochemistry, Genetics and Molecular Biology 25 17%
Agricultural and Biological Sciences 19 13%
Medicine and Dentistry 8 5%
Chemistry 5 3%
Other 15 10%
Unknown 43 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2023.
All research outputs
#1,831,610
of 25,059,640 outputs
Outputs from Molecular Neurodegeneration
#180
of 955 outputs
Outputs of similar age
#40,252
of 449,792 outputs
Outputs of similar age from Molecular Neurodegeneration
#2
of 18 outputs
Altmetric has tracked 25,059,640 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 955 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,792 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.